Meningitis Outbreak in Kent Prompts Vaccine Eligibility Review
The UK Health Security Agency has confirmed 18 cases of meningitis linked to an outbreak in Kent, with an additional 11 cases currently under investigation. This development has prompted health experts to reconsider the eligibility criteria for the meningitis B vaccine, as concerns mount over potential spread during the upcoming Easter holidays.
Expert Committee to Examine Vaccine Expansion
The Joint Committee on Vaccination and Immunisation has initiated a review at the request of Health Secretary Wes Streeting, who called for a re-examination of meningitis vaccine eligibility. The committee, which advises all four UK nations on immunisation policy, is evaluating whether to recommend routine MenB vaccinations for a broader demographic beyond the current infant-focused programme.
Historically, the JCVI has deemed catch-up campaigns for individuals born before 2015, when the MenB jab was introduced for infants, as not cost-effective. Experts note that vaccine protection is temporary and does not prevent bacterial transmission.
Risk of Spread During Easter Travel
Dr Anjan Ghosh, Director of Public Health at Kent County Council, warned that sporadic cases could emerge across the UK as students return home for Easter. He outlined three potential scenarios over the next month: containment within Kent, isolated household clusters outside the county, or a worst-case scenario of a new cluster elsewhere. However, he emphasised that the latter two outcomes are highly unlikely.
Ghosh stated, "We fully expect the growth in cases to slow after a month, but it is too early to definitively say if the outbreak has peaked."
Campaign for Change Following Tragic Loss
The family of Juliette Kenny, a teenager who died from meningitis on March 15, is advocating for routine vaccination access for teenagers and young people. Her father, Michael Kenny, expressed, "No family should experience this pain and tragedy. We want Juliette's legacy to be lasting change."
Expert Opinions on Vaccine Policy
Dr Michael Head, a senior research fellow in Global Health at the University of Southampton, suggested that adding MenB to routine year 9 vaccinations could be a viable option. He said, "There would certainly be value in an updated review by the JCVI to understand the benefit of a booster rollout in teenagers. School-based immunisation already includes the MenACWY vaccine, making this a simplified approach."
In contrast, Professor Andy Pollard, Director of the Oxford Vaccine Group, expressed skepticism about policy changes, citing Treasury constraints on cost-effectiveness. He noted, "While there is clear potential health benefit, the JCVI is unlikely to recommend expansion unless circumstances change, such as more cases or observed wider benefits."
Vaccine Availability and Response Efforts
The UKHSA confirmed that initial genetic analysis indicates the Bexsero vaccine offered in Kent should be effective against the outbreak strain, which belongs to group B meningococci and has circulated in the UK for about five years.
NHS Kent and Medway reported that over 4,500 people have been vaccinated, with 10,561 doses of antibiotics distributed. Ed Waller, Deputy Chief Executive, assured, "We have ample vaccine stocks in Kent and will draw more from national reserves to maximise capacity over the weekend."
As queues for vaccinations continued throughout Friday, officials stressed that sufficient supplies are available to manage the outbreak and protect public health.
